Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
A Phase I trial in about 50 healthy volunteers showed that single and multiple ascending-doses of EB-1020 were well tolerated. Neurovance plans to start Phase IIa testing of EB-1020 in mid-2013 with d...